Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis
NCT06628206Phase 1Active, not recruiting
- Sponsor
- LAPIX Therapeutics
- Start
- Dec 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of lpx-ti641 in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) (2 arms), sponsored by LAPIX Therapeutics. Primary endpoint: Safety and Tolerability at 56 days. Started Dec 2024; status: active, not recruiting.
02
Drugs
lpx-ti641
03
Conditions
rheumatoid arthritis (RA)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT06628206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06628206.